Month: January 2022

Duke Realty Corporation (NYSE: DRE) Announces the Income Tax Characteristics of its 2021 Common Share Dividends

Written by Customer Service on January 18, 2022. Posted in Dividend Reports And Estimates.

INDIANAPOLIS, Jan. 18, 2022 (GLOBE NEWSWIRE) — Duke Realty Corporation (NYSE: DRE) announces the income tax characteristics of its 2021 common share dividends. Shareholders are encouraged to consult with their personal tax advisors as to their specific tax treatment of Duke Realty Corporation’s dividends. Common Share Dividends:Ticker Symbol DRE, CUSIP # 264411505PaymentDate Total 2021DistributionPer ShareTotalOrdinaryDividendsQualifiedDividends (1) Total CapitalGainDistributionUnrecapturedSection 1250Gain(2) Section199ADividends(3)Form 1099-DIV BoxNumber 1a 1b 2a 2b 52/26/2021 $0.255000 $0.233247 $0.012764 $0.021753 $0.010730 $0.2204836/1/2021 0.255000 0.233247 0.012764 0.021753 0.010730 0.2204838/31/2021 0.255000 0.233247 0.012764 0.021753 0.010730 0.22048311/30/2021 0.280000 0.256114 0.014015 0.023886 0.011782 0.2420992021...

Chicken Soup for the Soul Entertainment Announces Timing of Regular Monthly Dividend for February for Series A Cumulative Redeemable Perpetual Preferred Stock

Written by Customer Service on January 18, 2022. Posted in Dividend Reports And Estimates.

COS COB, Conn., Jan. 18, 2022 (GLOBE NEWSWIRE) — Chicken Soup for the Soul Entertainment Inc. (Nasdaq: CSSE, CSSEP, CSSEN), one of the largest operators of streaming advertising-supported video on-demand (“AVOD”) networks, today announced the timing for the payment of its declared regular monthly dividend of $0.2031 per share of its 9.75% Series A Cumulative Redeemable Perpetual Preferred Stock for February 2022. The dividend will be payable on February 15, 2022 to holders of record as of January 31, 2022. The dividend will be paid in cash. ABOUT CHICKEN SOUP FOR THE SOUL ENTERTAINMENT Chicken Soup for the Soul Entertainment, Inc. (Nasdaq: CSSE) (the “Company”) operates streaming video-on-demand networks (VOD). The Company owns Crackle Plus, which owns and operates a variety of ad-supported and subscription-based VOD networks including...

Orion Energy Systems Preliminarily Expects Q3’22 Revenue of Approximately $30.5M, Reduces FY 2022 Revenue Outlook to $130M and Holds Investor Call Today at 5:00pm ET

Written by Customer Service on January 18, 2022. Posted in Public Companies.

MANITOWOC, Wis., Jan. 18, 2022 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, controls and IoT systems, including turnkey project implementation, program management and system maintenance, announced today that it preliminarily expects revenue of approximately $30.5M for its FY 2022 third quarter ended December 31, 2021. Due to customer delays on several larger LED lighting and controls projects, primarily caused by the response of customers to supply chain disruptions and COVID-19 related impacts to their businesses, Orion now anticipates FY 2022 revenue of approximately $130M, as compared to its prior expectation of at least $150M. Orion’s updated FY 2022 revenue outlook represents growth of approximately 11% over FY 2021 revenue of $116.8M. Orion will...

JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN

Written by Customer Service on January 18, 2022. Posted in Public Companies.

Mechelen, Belgium; 18 January 2022; 22.01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Jyseleca®(filgotinib 200mg tablets), as a new treatment for ulcerative colitis (UC) for Great Britain. The MHRA has licensed an additional indication for Jyseleca, an oral once-daily, JAK1 preferential inhibitor, for use in adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. The submission was supported by data from the Phase 2b/3 SELECTION program, published in the Lancet1. The decision from the MHRA follows authorisation from the European Commission (EC) for use in the same patient population. Michele...

Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

Written by Customer Service on January 18, 2022. Posted in Public Companies.

DURHAM, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that a peer-reviewed article entitled, “Phase 2 Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma (PC-PG) and Desmoplastic Small Round Cell Tumor (DSRCT),” has been published in the journal, Clinical Cancer Research. The article can be accessed here. An interim summary of select cohorts from this study was previously presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2021. ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist. “Given ONC201’s demonstrated...

NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies”

Written by Customer Service on January 18, 2022. Posted in Public Companies.

GAITHERSBURG, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in the LLS TAP panel discussion entitled “Expanding the Possible with Next Generation Cell Therapies” on Friday, January 21, 2022 at 12:00 p.m. Eastern Time. The webcast will be accessible on the Investor Relations page of NexImmune’s website at Events and Presentations | NexImmune, Inc. Participants may also register at LLS TAP: Expanding the Possible with Next-Generation Cell Therapies. LLS and NexImmune have a long history of working together. In October 2017, NexImmune benefitted...

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022

Written by Customer Service on January 18, 2022. Posted in Public Companies.

— Meeting to Reconvene on March 24, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders (EGM) on January 18, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021 (Proxy Statement). The EGM will reconvene on Thursday, March 24, 2022, beginning at 5:00 p.m. Irish time (12:00 p.m., U.S. Eastern Time) at 25-28 North...

NeoGames S.A. announces a recommended public offer to the shareholders of Aspire Global plc

Written by Customer Service on January 18, 2022. Posted in Mergers And Acquisitions.

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT INFORMATION” AT THE END OF THIS ANNOUNCEMENT AND IN THE OFFER DOCUMENT WHICH WILL BE PUBLISHED SHORTLY BEFORE THE BEGINNING OF THE ACCEPTANCE PERIOD FOR THE OFFER. SHAREHOLDERS IN THE UNITED STATES SHOULD ALSO REFER TO THE SECTION TITLED “SPECIAL NOTICE TO SHAREHOLDERS IN THE UNITED...

Kadant Receives Environmental Initiatives Award from SEAL Business Sustainability Awards

Written by Customer Service on January 18, 2022. Posted in Public Companies.

WESTFORD, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) — Kadant Inc. (NYSE: KAI) announced today that it was selected as a winner of the 2021 SEAL Business Sustainability Award in the Environmental Initiatives category. The SEAL Awards recognize companies across the globe that make measurable contributions to sustainability and develop innovative initiatives that positively impact the environment. “We are proud to be recognized by SEAL Awards for our environmental stewardship and commitment to sustainable business practices,” said Jeffrey L. Powell, president and chief executive officer of Kadant. “Kadant has a deep heritage of developing technologies and solutions that support sustainable industrial processing, and we are honored to be recognized for our efforts.” The SEAL (Sustainability, Environmental Achievement and Leadership) Awards...

First Central Savings Bank Reports Record Calendar Fourth Quarter 2021 Results Highlighted by Record Operating and Cash Earnings, Excellent Balance Sheet Growth, Strong Net Interest Margin, and Exceptional Asset Quality

Written by Customer Service on January 18, 2022. Posted in Earnings Releases And Operating Results.

Performance HighlightsOperating and Cash Earnings: Net income for the quarter ended December 31, 2021 was a record $3.2 million or $0.30 per share, compared to a net loss of $568 thousand or ($0.05) per share recorded in the prior year quarter ended December 31, 2020. Cash earnings for the quarter ended December 31, 2021 were a record $4.8 million, or $0.46 per share, an increase of $3.3 million, or 219.0%, from $1.5 million, or $0.15 per share, for the prior year quarter. Net income for the twelve months ended December 31, 2021 was $8.7 million or $0.82 per share, compared to $1.5 million or $0.14 per share recorded in the prior year twelve months ended December 31, 2020, representing a 501.4% increase in year to date net income year-over-year. Record Financial Performance Metrics: Return on average assets and average stockholders’...

Month: January 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals